Table 2. Sub-analysis of pivotal trials with iSGLT2 in older population.

	N	Older patients	HR (95% CI)
CI: confidence interval; CV: cardiovascular; HF: heart failure; HR: hazard ratio; iSGLT2: inhibitors of sodium-glucose linked transporter-2; MACE: major adverse cardiac events; MI: myocardial infarction.
Empagliflozin[34]	7,020	≥ 75 years: 652	3P-MACEAll: 0.86 (0.74-0.99)≥ 75 years: 0.68 (0.46-1.00)Cardiovascular deathAll: 0.62 (0.49-0.77)≥ 75 years: 0.55 (0.32-0.94)HF hospitalisation All: 0.65 (0.50-0.85)≥ 75 years: 0.45 (0.22-0.89)
Dapagliflozin[54]	4,744	≥ 75 years: 1,149	Combined HF hospitalisation/CV death All: 0.68 (0.53-0.88)
Dapagliflozin[36]	17,160	≥ 75 years: 1,096	Combined HF hospitalisation/CV death All: 0.94 (0.65-1.36)
Canagliflozin[26]	10,142	≥ 75 years: 4,564	CV death, non-fatal MI or non-fatal strokeAll: 0.86 (0.75-0.97)≥ 75 years: 0.80 (0.67-0.95)Hospitalisation for HFAll: 0.67 (0.52-0.87)≥ 75 years: 0.65 (0.47-0.90)
Ertugliflozin[37]	8,238	≥ 75 years: 903	CV death, non-fatal MI or non-fatal strokeAll: 0.97 (0.85-1.11)≥ 65 years: 1.03 (0.86-1.22)
Sotagliflozin[38]	1,222	≥ 65 years: 858	CV death, hospitalisation and urgent care for HFAll: 0.67 (0.52-0-85)≥ 65 years: 0.62 (0.47-0.82)